Empagliflozin Reversal of Arterial StiffnEss in Aging
Recruiting
Phase 2
Phase 3
Interventional Study
Aging
Arterial Stiffness
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 60 – 80
- Sex
- Any
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 80 (estimated)
- Sponsor
- University of Missouri-Columbia · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Randomized placebo-controlled clinical trial in a cohort of males (n=40) and females (n=40), 60-80 years of age, with the hypothesis that SGLT2 inhibition with empagliflozin (10mg/day for 12 weeks) reduces aging-related arterial stiffening.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Able to provide consent
* 60 to 80 years of age at randomization (women must be postmenopausal defined as more than 1 year without menses)
* Stable anti-hypertensive medication regimen (if in use) for at least 90 days
* Evidence of arterial stiffening (defined as carotid-femor…
Contacts